However, this gene overexpression was detected in various blood disorders, including myelodysplastic syndromes (MDS), Hodgkin’s lymphoma (HL), multiple myeloma (MM) and T-cell acute lymphoblastic leukemia (T-ALL), implying the need to inhibit KDM6B for successful cancer therapy [36,37,38]. This evidence concerns the gene KDM6B and hematologic disorder.